IP Library Granted Patent US 11,634,401
Granted Patent B2
US 11,634,401 · App. 17/141,472 · Granted Apr 25, 2023

Process-scale synthesis of urolithin A

Inventors: Wolfgang Skranc (Vienna, AT); George Yiannikouros (Florence, SC); Alexander Trofimov (Florence, SC); Zhixing Shan (Albany, NY); Christopher Goss (Florence, SC)
Assignee: Amazentis SA
C07D311/80B01J27/055
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,634,401
App. No.
17/141,472
Granted
Apr 25, 2023
Kind
B2
Abstract

Disclosed are methods for preparing a salt of urolithin A and, in turn, urolithin A. The methods are advantageous for the large-scale preparation of urolithin A or a pharmaceutically acceptable salt thereof.

Claims (23)

1. A method of preparing a salt of urolithin A, comprising: combining in an alkaline aqueous solution a copper-containing catalyst, 2-bromo-5-hydroxybenzoic acid, and resorcinol, thereby forming the salt of urolithin A; wherein the amount of the copper-containing catalyst is at least a trace amount but no more than 0.01 molar equivalents relative to the amount of 2-bromo-5-hydroxybenzoic acid; and the molar ratio of resorcinol to 2-bromo-5-hydroxybenzoic acid is about 3.5:1 to about 5:1.

2. The method of claim 1 , wherein the copper-containing catalyst is selected from the group consisting of copper powder, copper-bronze couple, CuSO 4 pentahydrate, CuSO 4 hydrate, anhydrous CuSO 4 , Cu(acac) 2 , CuCl, CuCl 2 , CuBr, CuBr 2 , CuI, Cu 2 O, CuO, CuOTf, CuCN, and mixtures thereof.

3. The method of claim 1 , wherein the alkaline aqueous solution comprises LiOH, NaOH, KOH, CsOH, Na 2 CO 3 , CaCO 3 , or Cs 2 CO 3 .

4. The method of claim 1 , wherein the alkaline aqueous solution comprises LiOH, NaOH, KOH, CsOH, Na 2 CO 3 , CaCO 3 , or Cs 2 CO 3 ; and the molar ratio of LiOH, NaOH, KOH, CsOH, Na 2 CO 3 , CaCO 3 , or Cs 2 CO 3 to 2-bromo-5-hydroxybenzoic acid is about 2.8:1 to about 5:1.

5. The method of claim 1 , wherein the molar yield of the salt of urolithin A is at least about 40% relative to the amount of 2-bromo-5-hydroxybenzoic acid.

6. The method of claim 1 , wherein the salt of urolithin A is urolithin A monosodium salt.

7. The method of claim 1 , wherein the salt of urolithin A is urolithin A disodium salt.

8. The method of claim 1 , wherein the alkaline aqueous solution is heated at a temperature in the range of about 60° C. to about 90° C.

9. The method of claim 1 , further comprising isolating the salt of urolithin A, to give an isolated salt of urolithin A.

10. The method of claim 9 , wherein the isolated salt of urolithin A is isolated by filtration.

11. The method of claim 9 , wherein the isolated salt of urolithin A contains less than about 1 ppm copper.

12. The method of claim 9 , further comprising combining a Bronsted acid and the isolated salt of urolithin A, to give a slurry.

13. The method of claim 12 , wherein the Bronsted acid is a carboxylic acid.

14. The method of claim 13 , wherein the carboxylic acid is acetic acid.

15. The method of claim 13 , wherein the carboxylic acid is glacial acetic acid.

16. The method of claim 9 , wherein the isolated salt of urolithin A is urolithin A monosodium salt.

17. The method of claim 9 , wherein the isolated salt of urolithin A is urolithin A disodium salt.

18. The method of claim 9 , wherein the isolated salt of urolithin is at least 95% pure.

19. The method of claim 12 , wherein the slurry is heated at a temperature in the range of about 100° C. to about 130° C.

20. The method of claim 12 , wherein the slurry is maintained at a temperature in the range of about 10° C. to about 30° C.

21. The method of claim 12 , further comprising isolating urolithin A from the slurry.

22. The method of claim 21 , wherein the urolithin A is isolated by filtration.

23. The method of claim 21 , wherein the isolated urolithin A is at least 99% pure.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 5, 2021
From: PATHEON AUSTRIA GMBH & CO KG
To: AMAZENTIS SA
Reel/Frame 054813/0921 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 5, 2021
From: SKRANC, WOLFGANG; YIANNIKOUROS, GEORGE; TROFIMOV, ALEXANDER; SHAN, ZHIXING; GOSS, CHRISTOPHER
To: PATHEON AUSTRIA GMBH & CO KG
Reel/Frame 054900/0084 →
Continuity (4)
Continuation 16287347 · Feb 27, 2019
Provisional Application 62765125 · Aug 17, 2018
Provisional Application 62635893 · Feb 27, 2018
Related Publication 20210198225A1 · Jul 1, 2021
Cited By (4)
US 12,338,224 US 12,544,358 US 12,576,064 US 12,576,065